Cortinovis Diego L, Canova Stefania, Abbate Marida, Colonese Francesca, Bidoli Paolo
SC Oncologia Medica, Ospedale San Gerardo , Monza , Italy.
Front Med (Lausanne). 2016 Dec 13;3:67. doi: 10.3389/fmed.2016.00067. eCollection 2016.
Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues. The main doubts regarding the optimal selection of the patient are the role of this drug in first line of treatment, the individualization of the correct methodology of radiologic assessment and efficacy analysis, the best management of immune-mediated adverse events, and how to overcome the immunoresistance. The aim of this review is to analyze literature data on nivolumab in lung cancer with a focus on critical aspects related to the drug in terms of safety, the use in clinical practice, and possible placement in the treatment algorithm.
免疫疗法正在改变非小细胞肺癌（NSCLC）的治疗方式。PD-1抑制剂纳武单抗已在疗效方面展现出显著成果，且安全性良好。使用免疫疗法治疗NSCLC的新方法仍存在未解决的问题和具有挑战性的难题。关于患者最佳选择的主要疑问包括该药物在一线治疗中的作用、放射学评估和疗效分析正确方法的个体化、免疫介导不良事件的最佳管理以及如何克服免疫抵抗。本综述的目的是分析关于纳武单抗治疗肺癌的文献数据，重点关注与该药物在安全性、临床实践中的应用以及治疗算法中可能的定位相关的关键方面。
